Dishman Carbogen Amcis
DCAL •NSE

Dishman Carbogen Amcis

₹115.57-2.96 (2.50%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
115.00
Today’s high
118.99
52 week low
116.60
52 week high
274.30
Open price
116.00
Previous close
118.53
Live volume
8,02,269
Lower circuit
104.02
Upper circuit
127.12

Fundamentals

Market Cap
₹1,859Cr
ROE
-1.74%
P/E Ratio(TTM)
--
EPS(TTM)
-7.39
P/B Ratio
0.28
Dividend Yield
0.00%
Industry P/E
40.13
Book Value
425.50
Debt to Equity
0.51
Face Value
2

Financial performance

Quarterly
Yearly
All Financials
SEP '26
₹511Cr
-26.57%
-₹66.73Cr
-15.29%
-2500312.5625937.5
Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Revenue growthValue
1Y (TTM)-23%
3Y CAGR+7.0%
Profit growthValue
3Y CAGR+74%

About

Dishman Carbogen Amcis Limited, or 'imdcal', epitomises excellence in Contract Research and Manufacturing Services (CRAMS), serving the global pharmaceutical and bio-technology industries. The company aims to be the preferred partner for customers to create a better world by developing and manufacturing complex substances and highly potent active ingredients. Its fundamental purpose is to support and assist people worldwide suffering from illness, ensuring that this help is delivered efficiently, comprehensively, and effectively. The company's integrated CRAMS offerings cover the entire drug development lifecycle, from process research and development to late-stage clinical and commercial manufacturing. Through proactive partnerships, it anticipates client needs and is driven by a mission to inspire science and revolutionize healthcare across the globe with high-value solutions. With a workforce of over 2,200 members and a footprint across India, Switzerland, the UK, France, and China, it exemplifies innovation and reliability.;
CEO/MD
Arpit J Vyas
Founded in
2007
NSE symbol
DCAL
Industry

Shareholding pattern

Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Shareholder details

Mutual Funds Invested (1)

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
₹20,642.00
-460.00 (2.18%)
L
    H
    27,061.5759.813.34
    ₹1,609.30
    +6.40 (0.40%)
    L
      H
      18,386.85--3.11
      ₹451.70
      +14.35 (3.28%)
      L
        H
        17,664.5694.923.64
        ₹462.30
        +2.85 (0.62%)
        L
          H
          17,568.13--4.49
          Livesquawk •
          DCAL posted a Q2 consolidated net loss of 667.3M rupees against a profit of 652.7M rupees YoY. The Q2 performance signals a sharp deterioration in earnings compared to a profitable period last year.
          2026
          13
          Nov
          Quarterly Result
          Release date
          14
          Aug
          Quarterly Result
          Release date
          19
          May
          Annual Result
          Release date
          3
          Feb
          Quarterly Result
          Release date
          2025
          4
          Nov
          Quarterly Result
          Release date
          12
          Aug
          Quarterly Result
          Release date
          Events calendar
          View upcoming events in other stocks